XNW-5004 is under clinical development by Evopoint Bioscience and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase II drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XNW-5004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XNW-5004 overview
XNW-5004 is under development for the treatment of relapse and refractory non-Hodgkin lymphoma (NHL) including relapsed or refractory follicular lymphoma, ALK-positive anaplastic large T-cell lymphoma, and ALK-negative anaplastic Large T-cell lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma, peripheral T-cell lymphomas , angioimmunoblastic t-cell lymphoma/immunoblastic lymphadenopathy, relapsed chronic lymphocytic, refractory chronic lymphocytic leukemia, Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), diffuse large b-cell lymphoma, metastatic castration-resistant prostate cancer (mCRPC), head and neck squamous cell carcinoma including nasopharyngeal carcinoma, urothelial carcinoma including urothelial carcinoma of bladder, renal pelvis, ureter, urethral origin, small-cell lung cancer, non-small cell lung cancer, cervical cancer and advanced solid tumors. The drug candidate is administered by oral route as tablet. It targets histone lysine N methyltransferase EZH2 (EZH2).
Evopoint Bioscience overview
Evopoint Bioscience, formerly Suzhou Sinovent Pharmaceuticals, is a biopharmaceutical company that involved in development of therapeutics for oncology, autoimmunity, and infectious diseases. The company is headquartered in Suzhou, Jiangsu, China.
For a complete picture of XNW-5004’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
